BR112021025383A2 - Metiltionínio para uso no tratamento de sinaptopatias - Google Patents
Metiltionínio para uso no tratamento de sinaptopatiasInfo
- Publication number
- BR112021025383A2 BR112021025383A2 BR112021025383A BR112021025383A BR112021025383A2 BR 112021025383 A2 BR112021025383 A2 BR 112021025383A2 BR 112021025383 A BR112021025383 A BR 112021025383A BR 112021025383 A BR112021025383 A BR 112021025383A BR 112021025383 A2 BR112021025383 A2 BR 112021025383A2
- Authority
- BR
- Brazil
- Prior art keywords
- synaptopathies
- methylthioninium
- treatment
- leucomethylthioninium
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
metiltionínio para uso no tratamento de sinaptopatias. a presente invenção refere-se de maneira geral, a métodos e materiais para o tratamento de sinaptopatias, com base no uso de sais de ácido leuco-metiltionínio, que são divulgados neste documento para aumentar os níveis de sinaptofisina em várias regiões do cérebro em doses terapeuticamente relevantes tanto em modelos animais de doença neurodegenerativa, quanto em animais normais.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1909506.6A GB201909506D0 (en) | 2019-07-02 | 2019-07-02 | Synaptopathies |
PCT/EP2020/068306 WO2021001326A1 (en) | 2019-07-02 | 2020-06-29 | Methylthioninium for use in the treatment of synaptopathies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021025383A2 true BR112021025383A2 (pt) | 2022-02-01 |
Family
ID=67540130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021025383A BR112021025383A2 (pt) | 2019-07-02 | 2020-06-29 | Metiltionínio para uso no tratamento de sinaptopatias |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220370470A1 (pt) |
EP (1) | EP3993805A1 (pt) |
JP (1) | JP2022538286A (pt) |
KR (1) | KR20220029711A (pt) |
CN (1) | CN114080224A (pt) |
AU (1) | AU2020300792A1 (pt) |
BR (1) | BR112021025383A2 (pt) |
CA (1) | CA3143787A1 (pt) |
GB (1) | GB201909506D0 (pt) |
IL (1) | IL289371A (pt) |
MX (1) | MX2021015288A (pt) |
WO (1) | WO2021001326A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2912571T3 (es) | 2006-07-11 | 2022-05-26 | Wista Lab Ltd | Procedimientos de síntesis y/o de purificación de compuestos de diaminofenotiazinio |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020040032A1 (en) | 2000-07-07 | 2002-04-04 | Glasky Michelle S. | Methods for stimulation of synthesis of synaptophysin in the central nervous system |
GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
PT2013191E (pt) | 2006-03-29 | 2010-10-29 | Wista Lab Ltd | Sais de 3,7-diamino-10h-fenotiazina e a sua utilização |
PT2167095T (pt) | 2007-06-19 | 2019-08-06 | Wista Lab Ltd | Compostos de fenotiazina para o tratamento de comprometimento cognitivo leve |
PL2205245T3 (pl) | 2007-10-03 | 2015-12-31 | Wista Lab Ltd | Zastosowanie terapeutyczne diaminofenotiazyn |
US9283230B2 (en) | 2011-02-11 | 2016-03-15 | Wista Laboratories Ltd. | Phenothiazine diaminium salts and their use |
KR102475825B1 (ko) | 2016-07-25 | 2022-12-08 | 위스타 레보레이토리스 리미티드 | 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage) |
GB201614834D0 (en) | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
JP6756661B2 (ja) | 2017-04-28 | 2020-09-16 | 日立オートモティブシステムズ株式会社 | 車両電子制御装置 |
-
2019
- 2019-07-02 GB GBGB1909506.6A patent/GB201909506D0/en not_active Ceased
-
2020
- 2020-06-29 CN CN202080048560.8A patent/CN114080224A/zh active Pending
- 2020-06-29 EP EP20737381.2A patent/EP3993805A1/en active Pending
- 2020-06-29 AU AU2020300792A patent/AU2020300792A1/en active Pending
- 2020-06-29 JP JP2021577316A patent/JP2022538286A/ja active Pending
- 2020-06-29 MX MX2021015288A patent/MX2021015288A/es unknown
- 2020-06-29 KR KR1020227003215A patent/KR20220029711A/ko unknown
- 2020-06-29 BR BR112021025383A patent/BR112021025383A2/pt unknown
- 2020-06-29 US US17/620,966 patent/US20220370470A1/en active Pending
- 2020-06-29 CA CA3143787A patent/CA3143787A1/en active Pending
- 2020-06-29 WO PCT/EP2020/068306 patent/WO2021001326A1/en unknown
-
2021
- 2021-12-26 IL IL289371A patent/IL289371A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021001326A1 (en) | 2021-01-07 |
JP2022538286A (ja) | 2022-09-01 |
KR20220029711A (ko) | 2022-03-08 |
EP3993805A1 (en) | 2022-05-11 |
IL289371A (en) | 2022-02-01 |
AU2020300792A1 (en) | 2022-02-24 |
MX2021015288A (es) | 2022-01-18 |
CN114080224A (zh) | 2022-02-22 |
US20220370470A1 (en) | 2022-11-24 |
GB201909506D0 (en) | 2019-08-14 |
CA3143787A1 (en) | 2021-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021001575A1 (es) | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1) | |
CY1121826T1 (el) | Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson | |
BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
ECSP20030074A (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
BR112018012327A2 (pt) | compostos de diamina-arilsulfonamida substituídos com hidroxialquilamina e hidroxicicloalquilamina com atividade seletiva em canais de sódio ativados por voltagem | |
BR112018000624A2 (pt) | compostos de indazol e azaindazol como inibidores de irak-4 | |
BR112018069789A2 (pt) | medicamento obtido pela combinação do agonista de fxr e arb | |
CO2017005834A2 (es) | Composición de liberación modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabólicos relacionados | |
BR112017026535A2 (pt) | composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto | |
BR112022007595A2 (pt) | Métodos para tratar doença de alzheimer | |
BR112018010564A2 (pt) | composições farmacêuticas compreendendo levodopa amida e usos das mesmas | |
BRPI0606502A2 (pt) | compostos; processo para a fabricação de compostos; composições farmacêuticas; método para o tratamento ou prevenção de doenças que são associadas com a modulação de receptores h3; método para o tratamento ou prevenção de obesidade em um ser humano ou animal; método de tratamento ou prevenção de diabetes tipo ii em um ser humano ou animal e usos de compostos | |
BR112017011838A2 (pt) | polímeros de ligação a prótons para administração oral | |
BR112021018156A2 (pt) | Antagonistas de ngf para uso médico | |
BR112017000398A2 (pt) | composto ou sal do mesmo, método de tratamento de uma infecção causada por dirofilaria immitis, e, kit. | |
BR112016029067A2 (pt) | ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios? | |
BR112019004248A2 (pt) | inibidores da dopamina-b-hidroxilase | |
BR112021022951A2 (pt) | Composições e métodos para o tratamento de doenças mediadas por atpase | |
CO2020006361A2 (es) | Tratamiento antisentido del síndrome de angelman | |
CL2020002317A1 (es) | Compuesto inhibidor de tirosina quinasa c-abl: modalidades y métodos de fabricación y uso | |
BR112021025383A2 (pt) | Metiltionínio para uso no tratamento de sinaptopatias | |
BR112018070514A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
BR112018073688A2 (pt) | método de tratamento de hiperglicemia | |
CY1121773T1 (el) | Χρηση του παλμιτοϋλοαιθανολαμιδιου σε συνδυασμο με οπιοειδη | |
CY1124229T1 (el) | Συνδυασμος τραζοδονης και γκαμπαπεντινης για την αντιμετωπιση του πονου |